Global Valvular Heart Diseases Market 2025-2035

Description

List of Tables

Global Valvular Heart Diseases Market Size, Share & Trends Analysis Report by Product Type (Patches, Valves, Grafts, Medications, and Others) by Treatment Type (Medication, Surgery, and Others) by End User (Hospitals, Specialty Clinics, and Others) and by Valve Position Segmentation (Aortic Valve, Mitral Valve, and Tricuspid and Pulmonary Valves) and (Forecast Period (2025-2035)

Industry Overview

Valvular heart disease market was valued at $19.8 billion in 2024 and is projected to reach $64.5 billion by 2035, growing at a CAGR of 11.4% during the forecast period (2025-2035). The rising incidence of valvular diseases globally is expected to propel the market for treatments for valvular heart disease (VHD). VHD develops due to disease or injury to one or more heart valves, which affects normal blood flow and frequently results in major health issues.

Advanced treatments are growing increasingly necessary as a result of the increase in VHD cases caused by ageing populations, especially in developed countries. Recent developments in medical technology, such as the development of minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR) and Transcatheter Mitral Valve Repair (TMVR), are driving market growth. These advancements provide superior patient results, quicker recovery periods, and a lower risk as compared to conventional surgeries.

Furthermore, bioprosthetic valves and innovative valve repair methods have emerged as essential components in the therapeutic environment, improving durability and lowering difficulties. Pharmaceutical therapies, such as diuretics and anticoagulants, continue to be essential for controlling symptoms and enhancing patients' quality of life. Increased healthcare spending, increased knowledge, and growing research towards genetic therapy and stem cell technologies, which promise future breakthroughs, are further factors driving the industry.

Market Dynamics

Rising Prevalence of Valvular Disorders

Increased cases of aortic stenosis, mitral regurgitation, and tricuspid valve disease, especially in aging populations. Growing comorbidities like hypertension, diabetes, and obesity amplify susceptibility to valvular heart diseases (VHD).

Advancements in Minimally Invasive Procedures

Adoption of Transcatheter Aortic Valve Replacement (TAVR) and other minimally invasive techniques is increasing due to Shorter recovery times, reduced surgical risks, and Strong clinical outcomes versus traditional open-heart surgeries.

Technological Innovation

Development of next-generation balloon-expandable, self-expanding, and mechanically expanded valves with enhanced durability. Integration of advanced imaging tools and robotic-assisted procedures improves precision and patient safety.

Rising Awareness & Screening Programs

Increasing awareness among healthcare providers and patients promotes early diagnosis and timely intervention, improving outcomes and increasing procedure volumes.

Market Segmentation

Based on the product type, the market is segmented into patches, valves, grafts, medications, and others.
Based on the treatment type, the market is segmented into medication, surgery, and others.
Based on the end user, the market is segmented into hospitals, specialty clinics, and others.
Based on the valve position segmentation, the market is segmented into aortic valve, mitral valve, and tricuspid and pulmonary valves.

Balloon-Expandable Valves: The Largest Segment in Market Growth

By product type, the valves segment is projected to lead the global valvular heart diseases market with the largest share. Valves are preferred due to ease of deployment, precise placement, suitability for patients with complex aortic anatomies, enhanced durability, and reduced paravalvular leakage. Rising prevalence of aortic stenosis, growing geriatric population, and increasing awareness of minimally invasive procedures drive demand. Leading players continue R&D to improve outcomes and patient eligibility.

Hospitals: Key Segment in Market Growth

Among end-user segments, hospitals represent the key driver of growth in the global valvular heart diseases market. Hospitals drive market growth due to advanced infrastructure, skilled cardiologists, capacity to handle complex procedures, hybrid operating rooms, and cutting-edge imaging technologies. Hospitals are central to clinical trials, training, and the adoption of next-generation valve technologies. Expanding healthcare infrastructure and rising cardiovascular disease prevalence reinforce hospitals as the key growth segment.

Regional Outlook

The global valvular heart diseases market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

India's Market Expands Rapidly in Asia-Pacific

India emerges as a high-growth market. The country's rapid expansion in healthcare infrastructure, increasing availability of tertiary cardiac centers, and growing middle-class population with higher disposable income are major growth drivers. The rising prevalence of aortic stenosis and mitral valve diseases, coupled with government initiatives to promote cardiac care accessibility, has led to a surge in the adoption of both surgical and minimally invasive valve replacement procedures. China follows closely, driven by government investments in healthcare infrastructure, expanding hospital networks, and rising awareness of early intervention for valvular disorders. Other countries, such as Japan and South Korea, additionally show steady growth, supported by technologically advanced cardiac care and aging populations with higher susceptibility to valvular heart conditions.

North America Maintains Strong Market Position

North America continues to hold a strong position in the global valvular heart disease (VHD) market, with the US emerging as the dominant country commanding a major share. The US market benefits from a well-established healthcare infrastructure, high adoption of advanced procedures such as transcatheter aortic valve replacement (TAVR), and robust reimbursement policies that facilitate patient access to innovative cardiac therapies. Additionally, the increasing prevalence of valvular disorders, rising awareness of minimally invasive treatment options, and significant investment in research and development further strengthen the market. Canada also contributes to the region's growth through universal healthcare access and growing patient awareness. The combined effect of technological advancements, skilled medical professionals, and supportive regulatory frameworks ensures that North America, led by the United States, remains the key driver of global VHD market growth, maintaining both leadership and sustained expansion opportunities.

Market Players Outlook

The major companies operating in the global valvular heart diseases market include Abbott Laboratories, Boston Scientific Corp., Edwards Lifesciences Corp., LivaNova Plc, Medtronic Plc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In August 2025, Medtronic plc launched a next-generation self-expanding TAVR valve featuring improved hemodynamic performance and enhanced deliverability for complex anatomies.
In May 2025, Edwards Lifesciences Corp. received FDA approval for its latest balloon-expandable TAVR system, designed to reduce paravalvular leak and improve long-term durability. Additionally, the company acquired JenaValve Technology and JC Medical to bolster its TAVR pipeline for aortic regurgitation therapy.
In January 2025, Abbott Laboratories expanded its TAVR presence in emerging markets, including India and Latin America, through partnerships with leading cardiac centers. The company also received FDA approval for its heart valve repair device, TriClip, designed to treat tricuspid regurgitation.
In May 2025, Boston Scientific Corp. completed a strategic acquisition of a medical device startup specializing in mechanically expanded valves, aiming to strengthen its TAVR portfolio. However, the company announced the discontinuation of its Acurate neo2 and Acurate Prime TAVR systems due to a failed clinical study and unclear regulatory paths in the U.S. and Europe. Investors
In May 2025, JenaValve Technology, Inc. initiated a multicenter clinical trial for its novel transapical TAVR system targeting patients with bicuspid aortic valves.
In April 2025, LivaNova PLC continues to focus on the development of innovative heart valve solutions, contributing to the diversification of treatment options in the VHD market.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global valvular heart diseases market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023955

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Valvular Heart Diseases Market Sales Analysis - Product Type | Treatment Type | End User | Valve Position Segmentation ($ Million)
Valvular Heart Diseases Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Valvular Heart Diseases Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Valvular Heart Diseases Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Valvular Heart Diseases Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Valvular Heart Diseases Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Valvular Heart Diseases Market Revenue and Share by Manufacturers
Valvular Heart Diseases Product Type Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boston Scientific Corp.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Edwards Lifesciences Corp.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. LivaNova Plc
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Medtronic Plc
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Valvular Heart Diseases Market Sales Analysis By Product Type ($ Million)

5.1. Patches
5.2. Valves
5.3. Grafts
5.4. Medications
5.5. Others

6. Global Valvular Heart Diseases Market Sales Analysis By Treatment Type ($ Million)

6.1. Medication
6.2. Surgery
6.3. Others

7. Global Valvular Heart Diseases Market Sales Analysis By End User ($ Million)

7.1. Hospitals
7.2. Specialty Clinics
7.3. Others

8. Global Valvular Heart Diseases Market Sales Analysis By Valve Position Segmentation ($ Million)

8.1. Aortic Valve
8.2. Mitral Valve
8.3. Tricuspid and Pulmonary Valves

9. Regional Analysis

9.1. North American Valvular Heart Diseases Market Sales Analysis - Product Type | Treatment Type | End User | Valve Position Segmentation ($ Million)
Macroeconomic Factors for North America
- 9.1.1. United States
- 9.1.2. Canada
9.2. European Valvular Heart Diseases Market Sales Analysis - Product Type | Treatment Type | End User | Valve Position Segmentation ($ Million)
Macroeconomic Factors for Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. France
- 9.2.6. Russia
- 9.2.7. Rest of Europe
9.3. Asia-Pacific Valvular Heart Diseases Market Sales Analysis - Product Type | Treatment Type | End User | Valve Position Segmentation ($ Million)
Macroeconomic Factors for Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.3.4. India
- 9.3.5. Australia & New Zealand
- 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 9.3.7. Rest of Asia-Pacific
9.4. Rest of the World Valvular Heart Diseases Market Sales Analysis - Product Type | Treatment Type | End User | Valve Position Segmentation ($ Million)
Macroeconomic Factors for the Rest of the World
- 9.4.1. Latin America
- 9.4.2. Middle East and Africa

10. Company Profiles

10.1. Abbott Laboratories
- 10.1.1. Quick Facts
- 10.1.2. Company Overview
- 10.1.3. Product Portfolio
- 10.1.4. Business Strategies
10.2. Artivion, Inc.
- 10.2.1. Quick Facts
- 10.2.2. Company Overview
- 10.2.3. Product Portfolio
- 10.2.4. Business Strategies
10.3. Boston Scientific Corp.
- 10.3.1. Quick Facts
- 10.3.2. Company Overview
- 10.3.3. Product Portfolio
- 10.3.4. Business Strategies
10.4. Braile Biomedica
- 10.4.1. Quick Facts
- 10.4.2. Company Overview
- 10.4.3. Product Portfolio
- 10.4.4. Business Strategies
10.5. Cardiac Dimensions
- 10.5.1. Quick Facts
- 10.5.2. Company Overview
- 10.5.3. Product Portfolio
- 10.5.4. Business Strategies
10.6. Cardiovalve
- 10.6.1. Quick Facts
- 10.6.2. Company Overview
- 10.6.3. Product Portfolio
- 10.6.4. Business Strategies
10.7. Corcym
- 10.7.1. Quick Facts
- 10.7.2. Company Overview
- 10.7.3. Product Portfolio
- 10.7.4. Business Strategies
10.8. CryoLife, Inc.
- 10.8.1. Quick Facts
- 10.8.2. Company Overview
- 10.8.3. Product Portfolio
- 10.8.4. Business Strategies
10.9. Edwards Lifesciences Corp.
- 10.9.1. Quick Facts
- 10.9.2. Company Overview
- 10.9.3. Product Portfolio
- 10.9.4. Business Strategies
10.10. JenaValve Technology
- 10.10.1. Quick Facts
- 10.10.2. Company Overview
- 10.10.3. Product Portfolio
- 10.10.4. Business Strategies
10.11. Johnson & Johnson MedTech
- 10.11.1. Quick Facts
- 10.11.2. Company Overview
- 10.11.3. Product Portfolio
- 10.11.4. Business Strategies
10.12. LifeNet Health
- 10.12.1. Quick Facts
- 10.12.2. Company Overview
- 10.12.3. Product Portfolio
- 10.12.4. Business Strategies
10.13. LivaNova PLC
- 10.13.1. Quick Facts
- 10.13.2. Company Overview
- 10.13.3. Product Portfolio
- 10.13.4. Business Strategies
10.14. Medtronic PLC
- 10.14.1. Quick Facts
- 10.14.2. Company Overview
- 10.14.3. Product Portfolio
- 10.14.4. Business Strategies
10.15. Peijia Medical
- 10.15.1. Quick Facts
- 10.15.2. Company Overview
- 10.15.3. Product Portfolio
- 10.15.4. Business Strategies
10.16. Pi-Cardia
- 10.16.1. Quick Facts
- 10.16.2. Company Overview
- 10.16.3. Product Portfolio
- 10.16.4. Business Strategies
10.17. Shockwave Medical
- 10.17.1. Quick Facts
- 10.17.2. Company Overview
- 10.17.3. Product Portfolio
- 10.17.4. Business Strategies
10.18. Symetis
- 10.18.1. Quick Facts
- 10.18.2. Company Overview
- 10.18.3. Product Portfolio
- 10.18.4. Business Strategies
10.19. Transcatheter Technologies
- 10.19.1. Quick Facts
- 10.19.2. Company Overview
- 10.19.3. Product Portfolio
- 10.19.4. Business Strategies
10.20. Venus MedTech
- 10.20.1. Quick Facts
- 10.20.2. Company Overview
- 10.20.3. Product Portfolio
- 10.20.4. Business Strategies